Publications by authors named "Erica Stringer-Reasor"

Claim this Profile
S
Socioeconomic- and Insurance-Based Inequities in Oncotype DX Testing and Score-Guided Treatment.
Courtney P Williams, Jessica Shuey, Joud El Dick, Nusrat Jahan, Erica Stringer-Reasor

Cancer Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial).
Maeve A Hennessy, Constantine Gatsonis, Heather Jacene, Roisin M Connolly, Brian L Burnette, Erica M Stringer-Reasor

Future Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Erica M Stringer-Reasor

J Natl Compr Canc Netw· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer.
Erica M Stringer-Reasor, Poornima Saha, Masha Kocherginsky, Ricardo Lastra, Gabrielle Baker

Breast Cancer Res Treat· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of visually and computationally-assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030).
Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, Vandana G Abramson, Adam Brufsky, Erica Michelle Stringer-Reasor

J Natl Cancer Inst· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer.
Paula I Gonzalez-Ericsson, Nisha Unni, Komal Jhaveri, Erica Stringer-Reasor, Qi Liu

Clin Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative [Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI.
Ameer Mansur, Jonathan E McConathy, Erica Stringer-Reasor, Gabrielle Rocque, Katia Khoury

J Nucl Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer.
Lior Z Braunstein, Melissa P Mitchell, Hanna Bandos, William M Sikov, Atif J Khan, Erica M Stringer-Reasor

Future Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy.
Rachel M Layman, Hyo S Han, Hope S Rugo, Erica M Stringer-Reasor, Jennifer M Specht

Lancet Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
Denise M Wolf, Christina Yau, Michael Campbell, Annuska Glas, Andrei Barcaru, Erica Stringer-Reasor

JCO Precis Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.
Nan Chen, Margarite Matossian, Poornima Saha, Murtuza Rampurwala, Salaija Kamaraju, Erica M Stringer-Reasor

Breast Cancer Res Treat· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Clinical Trial Eligibility and Enrollment among Women with Breast Cancer: Implications for Understanding Trial Disparities.
Nicole Reh, Nicole E Caston, Courtney P Williams, Sindhu R Dwarampudi, Ahmed Elkhanany, Erica Stringer-Reasor

Ann Surg Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors.
Geoffrey Bostany, Yanjun Chen, Liton Francisco, Chen Dai, Qingrui Meng, Erica Stringer-Reasor

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Katia Khoury, Jane L Meisel, Christina Yau, Hope S Rugo, Rita Nanda, Erica Stringer-Reasor

Nat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo, Erica Stringer-Reasor

Nat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast Cancer.
Bryan P Schneider, Fengmin Zhao, Tarah J Ballinger, Sofia F Garcia, Fei Shen, Erica M Stringer-Reasor

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Erica M Stringer-Reasor

J Natl Compr Canc Netw· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Erica M Stringer-Reasor

Nat Commun· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing inclusion and equity for Black women in breast cancer clinical trials.
Ammanuel Taye, Ahmed Elkhanany, Erica Stringer-Reasor

Clin Adv Hematol Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Rachel M Layman, Hyo S Han, Hope S Rugo, Erica M Stringer-Reasor, Jennifer M Specht

Lancet Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Erica M Stringer-Reasor

Nat Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Kathy S Albain, Christina Yau, Emanuel F Petricoin, Denise M Wolf, Julie E Lang, Erica Stringer-Reasor

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Filipa Lynce, Candace Mainor, Renee N Donahue, Xue Geng, Greg Jones, Erica M Stringer-Reasor

medRxiv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Erica M Stringer-Reasor

J Natl Compr Canc Netw· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between.
Hyo Sook Han, Praveen Vikas, Ricardo L B Costa, Nusrat Jahan, Ammanuel Taye, Erica M Stringer-Reasor

Am Soc Clin Oncol Educ Book· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis